Workflow
Warrior Met Coal(HCC)
icon
Search documents
Warrior Met Coal: Another Soft Quarter, But The Long-Term Potential Remains Appealing
Seeking Alpha· 2025-05-01 02:39
Company Overview - Warrior Met Coal (NYSE: HCC) is a U.S. metallurgical coal mining company focused on the export market [1] - The company operates two mines and is developing the Blue Creek project, all located in Alabama [1] Management and Operations - The company is noted for its good management team and consistent operations [1] - Quality of operations is emphasized, indicating a strong operational foundation [1] Investment Strategy - The investment strategy focuses on turnarounds in natural resource industries with a typical holding period of 2-3 years [2] - Emphasis on value investing provides good downside protection while allowing for significant upside potential [2] - The portfolio has achieved a compounded annual growth rate of 26% over the last 6 years [2]
Warrior Met Coal (HCC) Reports Q1 Loss, Tops Revenue Estimates
ZACKS· 2025-04-30 23:01
Warrior Met Coal (HCC) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to earnings of $2.63 per share a year ago. These figures are adjusted for non- recurring items. This quarterly report represents an earnings surprise of -220%. A quarter ago, it was expected that this company would post earnings of $0.53 per share when it actually produced earnings of $0.15, delivering a surprise of -71.70%. Over the last four quarters, the company h ...
Warrior Met Coal(HCC) - 2025 Q1 - Earnings Call Presentation
2025-04-30 20:48
First Quarter 2025 Results April 30, 2025 Forward-looking Statements This presentation contains, and of Warrior Met Coal, Inc.'s (the "Company", "WMC" or "Warrior") officers and representatives may from time to time make, forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, included in this presentation that address activities, even ...
Warrior Met Coal(HCC) - 2025 Q1 - Quarterly Report
2025-04-30 20:44
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________ to _____________ Commission File Number: 001-38061 Warrior Met Coal, Inc. (Exact name of registrant as specified in its charter) Delaware 81-0706839 (State ...
Warrior Met Coal(HCC) - 2025 Q1 - Earnings Call Transcript
2025-04-30 20:30
Warrior Met Coal (HCC) Q1 2025 Earnings Call April 30, 2025 04:30 PM ET Speaker0 Good afternoon. My name is Dovan, and I will be your conference operator today. At this time, I would like to welcome everyone to the Warrior First Quarter twenty twenty five Financial Results Conference Call. At this time, all lines are in listen only mode. Following the presentation, we will conduct a question and answer session. This call is being recorded and will be available for replay on the company's website. I would li ...
Warrior Met Coal(HCC) - 2025 Q1 - Quarterly Results
2025-04-30 20:05
Exhibit 99.1 Warrior Reports First Quarter 2025 Results Strong cost performance generated positive margins and positive operating cash flows despite weak steelmaking coal markets Startup of Blue Creek longwall on track, on budget, and on schedule for completion no later than Q2 2026 Full year outlook unchanged at this time BROOKWOOD, AL - April 30, 2025 - Warrior Met Coal, Inc. (NYSE: HCC) ("Warrior" or the "Company") today announced results for the first quarter of 2025. Warrior is the leading dedicated U. ...
Analysts Estimate Warrior Met Coal (HCC) to Report a Decline in Earnings: What to Look Out for
ZACKS· 2025-04-23 15:07
The market expects Warrior Met Coal (HCC) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended March 2025. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be release ...
Hanna Announces Private Placement of Convertible Debentures
GlobeNewswire· 2025-04-09 15:11
TORONTO, April 09, 2025 (GLOBE NEWSWIRE) -- Hanna Capital Corp. (the “Corporation”) is pleased to announce that it intends to raise gross proceeds of up to $500,000 through a non-brokered private placement of either (i) secured convertible debenture units (the “Debenture Units”) and/or (ii) units (the “Units”). Debenture Unit Offering Each Debenture Unit consists of $10,000 principal amount (the “Principal Amount”) of secured convertible debt (the “Debentures”) and 500,000 common share purchase warrants (th ...
Warrior Met Coal: Low-Cost Producer With Upside
Seeking Alpha· 2025-03-31 22:09
Analyst's Disclosure: I/we have a beneficial long position in the shares of HCC either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Even as far back as the 19th century, receiving a lump of coal for Christmas was a sign of wrongdoing. Today, in the 21st century, with ESG and ...
Tempest Reports Year End 2024 Financial Results and Provides Business Update
GlobeNewswire News Room· 2025-03-27 20:10
• Granted Both Orphan Drug & Fast Track designations for Amezalpat (TPST-1120) for the treatment of patients with Hepatocellular Carcinoma (HCC)• Announced Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line HCC Pivotal Trial• Received FDA “Study May Proceed” letter for Phase 2 trial of TPST-1495 for the treatment of Familial Adenomatous Polyposis (FAP) BRISBANE, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage bi ...